ABCG2 and lung carcinoma: The reproducible resistance mechanism observed in MIA PaCa-2 cells (Fig. 4e) was distinct from KRAS-mutant colon and lung cancer models, which evidenced neither ABCG2 upregulation (Supplementary Fig. 4d) nor resensitization to ERK inhibition by pharmacologic ABCG2 inhibition (Supplementary Fig. 4e).